Mingowood Pharmacal

Mingowood PharmacalMingowood PharmacalMingowood Pharmacal
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

  • Home
  • Technology
    • Our Science
    • Demonstration
    • Stability Studies
    • ATR-FTIR
    • Patents
    • FAQ
  • Solutions
    • For Pharma & Biotech
    • For Manufacturers
    • For Investors
  • Pipeline
  • About
    • Mission
    • The Problem We Solve
    • Licensing Model
    • Leadership
  • News
  • Contact
  • More
    • Home
    • Technology
      • Our Science
      • Demonstration
      • Stability Studies
      • ATR-FTIR
      • Patents
      • FAQ
    • Solutions
      • For Pharma & Biotech
      • For Manufacturers
      • For Investors
    • Pipeline
    • About
      • Mission
      • The Problem We Solve
      • Licensing Model
      • Leadership
    • News
    • Contact

Mingowood Pharmacal

Mingowood PharmacalMingowood PharmacalMingowood Pharmacal

Signed in as:

filler@godaddy.com

  • Home
  • Technology
    • Our Science
    • Demonstration
    • Stability Studies
    • ATR-FTIR
    • Patents
    • FAQ
  • Solutions
    • For Pharma & Biotech
    • For Manufacturers
    • For Investors
  • Pipeline
  • About
    • Mission
    • The Problem We Solve
    • Licensing Model
    • Leadership
  • News
  • Contact

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

The Science behind our Technology

In the fast-evolving cannabinoids market, maintaining the potency of active agents is crucial. We are dedicated to preserving the therapeutic benefits of cannabinoid compounds, such as CBDA, THCA, and CBGA.


Introducing Intercalyx™: Our patented technology achieves over 90% encapsulation efficiency for acidic cannabinoids, ensuring maximum potency, stability, and long-term effectiveness.


Key Benefits Include:

  • Long-Term Stability and Protection: 
    • Intercalyx™ selectively encases acidic cannabinoids (CBDA, THCA, and CBGA) to prevent degradation, ensuring accurate dosing and sustained product effectiveness. 
    • Strongly inhibits the formation of degradants, including scheduled compounds like Δ-9 tetrahydrocannabinol (THC).
  • THCA Stability and Non-Psychoactive Properties: 
    • THCA does not convert to Δ-9 in vivo; it is metabolized into 11-hydroxy compounds without psychotropic effects.
  • Processable and Scalable Formulation: 
    • The combination of Intercalyx™ technology and acidic cannabinoids produces a fine powder using inexpensive, considered-safe pharmaceutical-grade excipients.
    • Validated scalability ensures efficient production.
  • Versatile Delivery and Administration: 
    • The finished product can be used in various delivery systems and routes of administration, including dispersions, emulsions, injectables, sublingual, oral, and inhalation.
    • Intercalyx™ technology provides taste and smell masking, enhancing user experience.
  • Regulatory-Friendly Formulation: 
    • Avoids creating new chemical entities (NCEs), expedites market entry, and efficiently navigates regulatory obstacles.
    • Pharmaceutical-grade formulation.
    • Intercalyx™ technology enables flexibility in equipment and starting materials. 
  • Temperature Resilience: 
    • Eliminates the need for complex cold storage by providing unparalleled protection against elevated temperatures.
  • Prevention of Degradation: 
    • Prevents decarboxylation and oxidation.
  • Precise Dosing: 
    • Ensures accurate and consistent dosing.


Our formulation employs cost-effective pharmaceutical-grade ingredients and standard pharmaceutical processes, resulting in Intercalyx™ intercalated material. These intercalates ensure efficient delivery, can be tailored for various routes of administration, and meet stringent regulatory standards.


Want the full technical overview?

Request a Mingowood Technology Overview, including stability studies and encapsulation efficiency data. 

Request Technical Overview

Mingowood Pharmacal

Copyright © 2024 Mingowood Pharmacal - All Rights Reserved.

Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept